Schnittger and colleagues reported on 252 NPM1-mutated AML patients, of whom 53 underwent allogeneic HSCT.12 However, their analyses were primarily focused on the correlation of outcome with MRD levels after chemotherapy. This evidence concerns the gene NPM1 and acute myeloid leukemia.